GPR40 Agonists for Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 diabetes mellitus, such as biguanides and PPAR gamma agonists, have limitations including side effects like lactic acidosis, nausea, diarrhea, and hypoglycemia, and do not effectively improve lipid metabolism or preserve islet function, leading to the need for daily insulin injections over time.
Innovation Solution
Development of novel substituted compounds that act as agonists for G-protein-coupled receptor 40 (GPR40), which are glucose-dependent, reducing the risk of hypoglycemia and targeting islet cells to restore or preserve islet function, thereby improving glucose and lipid metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biguanides (phenformin, metformin) are used to treat Type 2 diabetes, then hepatic glucose production is inhibited, but lactic acidosis and gastrointestinal side effects occur
Solution Approach 1:
The patent extracts and isolates the beneficial glucose-lowering effect from the harmful side effects by targeting a specific receptor (GPR40) that is predominantly expressed in pancreatic beta cells. This selective targeting approach separates the therapeutic action (enhancing glucose-dependent insulin secretion) from the adverse effects associated with non-selective biguanide mechanisms, thereby resolving the contradiction between efficacy and safety.
Solution Approach 2:
The invention applies local quality by designing a compound that acts specifically on pancreatic beta cells through GPR40 receptor activation. The drug's action is localized to the islet cells where GPR40 is highly expressed, rather than affecting hepatic glucose production systemically. This localized mechanism enhances insulin secretion only in the presence of glucose (avoiding hypoglycemia) and spares other tissues from unwanted effects, thus resolving the safety- efficacy contradiction.
2Reliability
If PPAR gamma agonists (rosiglitazone, pioglitazone) are used to treat Type 2 diabetes, then insulin resistance is improved, but lipid metabolism is not effectively improved and side effects occur
Solution Approach 1:
The patent extracts the beneficial insulin-sensitizing effect while eliminating the harmful lipid metabolic side effects by targeting GPR40 in pancreatic beta cells. Unlike PPAR gamma agonists that act systemically on adipose tissue and liver (affecting both glucose and lipid metabolism with adverse consequences), this invention selectively enhances glucose-dependent insulin secretion without the detrimental effects on lipid profile and cardiovascular safety observed with thiazolidinediones.
3Reliability
If sulfonylureas (tolbutamide, glipizide, glimepiride) are used to stimulate insulin secretion, then blood glucose is reduced, but hypoglycemia occurs requiring careful control
Solution Approach 1:
The patent applies dynamics by creating a glucose-dependent insulin secretion mechanism. The GPR40 agonist compounds enhance insulin secretion only in the presence of elevated glucose levels, making the drug's effect dynamic and responsive to the body's metabolic state. This contrasts with sulfonylureas that cause insulin secretion regardless of glucose levels, leading to hypoglycemia. The dynamic, glucose-sensing mechanism of GPR40 activation automatically prevents hypoglycemia while maintaining effective glucose control.
4Reliability
If current diabetes treatments are used long-term, then glucose control is achieved, but islet function declines requiring daily insulin injections
Solution Approach 1:
The patent applies preliminary action by using GPR40 agonists to protect and preserve beta cell function before complete failure occurs. By chronically stimulating GPR40 receptors in pancreatic beta cells, the compounds enhance insulin secretion capacity and protect against beta cell exhaustion and apoptosis. This preliminary protective action maintains endogenous insulin production capability over time, delaying or preventing the need for exogenous insulin injections, thereby addressing the long-term islet function decline problem.
Data Source
AI summary
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.